8-K

0001193125-24-078597.txt : 20240327 0001193125-24-078597.hdr.sgml : 20240327 20240327133705 ACCESSION NUMBER: 0001193125-24-078597 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240327 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scilex Holding Co CENTRAL INDEX KEY: 0001820190 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39852 FILM NUMBER: 24788610 BUSINESS ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: (650) 516-4310 MAIL ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Scilex Holding Company/DE DATE OF NAME CHANGE: 20221117 FORMER COMPANY: FORMER CONFORMED NAME: Vickers Vantage Corp. I DATE OF NAME CHANGE: 20200804 8-K 1 d800081d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 27, 2024

SCILEX HOLDING COMPANY

(Exact name of registrant as specified in its charter)


Delaware	001-39852	92-1062542
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

960 San Antonio Road, Palo Alto, California, 94303

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (650) 516-4310

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	SCLX	The Nasdaq Stock Market LLC
Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share	SCLXW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01.

Other Events.

On March 27, 2024, Scilex Holding Company (the “Company”) issued a press release announcing that the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”) has extended the expiration of the restrictions on transfer of the shares of the Company’s common stock that were previously distributed by Sorrento Therapeutics, Inc. (“Sorrento”), the Company’s former controlling stockholder, to Sorrento’s stockholders as a dividend on January 19, 2023 (the “Dividend Stock”). Such lock-up period was previously set to expire on March 31, 2024. On March 26, 2024, the Court approved a motion to extend the lock-up period of the Dividend Stock to September 30, 2024 (subject to certain qualifications as set forth in the press release). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description

99.1		Press Release, dated March 27, 2024.

104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


SCILEX HOLDING COMPANY

By:		/s/ Jaisim Shah
Name:		Jaisim Shah
Title:		Chief Executive Officer and President

Date: March 27, 2024

EX-99.1 2 d800081dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

FOR IMMEDIATE RELEASE

March 27, 2024

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend

PALO ALTO, CALIFORNIA – March 27, 2024 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”) has extended the expiration of the restrictions on transfer of the shares of common stock of Scilex that were previously distributed by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), Scilex’s former controlling stockholder, to Sorrento’s stockholders as a dividend on January 19, 2023 (the “Dividend Stock”). Such lock-up period was previously set to expire on March 31, 2024. On March 26, 2024, the Court approved a motion to extend the lock-up period of the Dividend Stock to the earlier of (i) September 30, 2024 or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agree in writing or on the record in Sorrento’s chapter 11 cases certain claims that may be asserted in potential litigation to avoid Sorrento’s distribution of Dividend Stock and to recover such Dividend Stock (the “Stock Clawback Claims”) should not be pursued, or on such date that the Court deems just and proper. The Court did not make any determination regarding the merits of the Stock Clawback Claims.

Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of and the holders of Dividend Stock would be prohibited from causing or encouraging any third party to do the same. The foregoing extension shall apply only to the Dividend Stock and does not apply to any other outstanding securities of Scilex.

To review the Court order, please click the link here.

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^® , the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, expected to launch in the first half of 2024.

Page | 1

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA^TM” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which Scilex has completed a Phase 3 study and has granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which Scilex has recently completed a Phase 2 trial in low back pain. SP-103 has granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024.

Scilex Holding Company is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding any early expiration of the restrictions on transfer of the Dividend Stock, Scilex’s expectation to launch Gloperba^® in the first half of 2024 and plans to initiate a Phase 2 clinical trial in 2024 for SP-104.

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA^™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual

Page | 2

Report on Form 10-K for the year ended December 31, 2023, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

Investors and Media

Scilex Holding Company

960 San Antonio Road

Palo Alto, CA 94303

Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

# # #

SEMDEXA^™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

All other trademarks are the property of their respective owners.

Page | 3

EX-101.SCH 3 sclxw-20240327.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 sclxw-20240327_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sclxw-20240327_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Par Value 0.0001 Per Share 2 [Member] Common Stock Par Value 0.0001 Per Share 2 [Member] Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member] Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member] EX-101.PRE 6 sclxw-20240327_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g800081g0327104301100.jpg GRAPHIC begin 644 g800081g0327104301100.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 27, 2024
Document And Entity Information [Line Items]
Entity Registrant Name	Scilex Holding Co
Amendment Flag	false
Entity Central Index Key	0001820190
Document Type	8-K
Document Period End Date	Mar. 27, 2024
Entity Incorporation State Country Code	DE
Entity File Number	001-39852
Entity Tax Identification Number	92-1062542
Entity Address, Address Line One	960 San Antonio Road
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94303
City Area Code	(650)
Local Phone Number	516-4310
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Common Stock Par Value 0.0001 Per Share 2 [Member]
Document And Entity Information [Line Items]
Security 12b Title	Common stock, par value $0.0001 per share
Trading Symbol	SCLX
Security Exchange Name	NASDAQ
Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]
Document And Entity Information [Line Items]
Security 12b Title	Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share
Trading Symbol	SCLXW
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d800081d8k.htm 7 d800081d8k.htm sclxw-20240327.xsd sclxw-20240327_def.xml sclxw-20240327_lab.xml sclxw-20240327_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d800081d8k.htm": { "nsprefix": "sclxw", "nsuri": "http://imetrix.edgar-online.com/20240327", "dts": { "inline": { "local": [ "d800081d8k.htm" ] }, "schema": { "local": [ "sclxw-20240327.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "sclxw-20240327_def.xml" ] }, "labelLink": { "local": [ "sclxw-20240327_lab.xml" ] }, "presentationLink": { "local": [ "sclxw-20240327_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-27_to_2024-03-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d800081d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-27_to_2024-03-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d800081d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "sclxw_CommonStockParValue0.0001PerShare2Member": { "xbrltype": "domainItemType", "nsuri": "http://imetrix.edgar-online.com/20240327", "localname": "CommonStockParValue0.0001PerShare2Member", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock Par Value 0.0001 Per Share 2 [Member]", "terseLabel": "Common Stock Par Value 0.0001 Per Share 2 [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "sclxw_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://imetrix.edgar-online.com/20240327", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "sclxw_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://imetrix.edgar-online.com/20240327", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member": { "xbrltype": "domainItemType", "nsuri": "http://imetrix.edgar-online.com/20240327", "localname": "WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]", "terseLabel": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://imetrix.edgar-online.com//20240327/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001193125-24-078597-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-078597-xbrl.zip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end XML 20 d800081d8k_htm.xml IDEA: XBRL DOCUMENT 0001820190 2024-03-27 2024-03-27 0001820190 sclxw:CommonStockParValue0.0001PerShare2Member 2024-03-27 2024-03-27 0001820190 sclxw:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member 2024-03-27 2024-03-27 Scilex Holding Co false 0001820190 8-K 2024-03-27 DE 001-39852 92-1062542 960 San Antonio Road Palo Alto CA 94303 (650) 516-4310 false false false false Common stock, par value $0.0001 per share SCLX NASDAQ Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share SCLXW NASDAQ true true